Section 5

510(k) Summary

(in accordance with 21 CFR 807.92)

Date: December 18, 2015

Submitter:
Haemonetics Corporation
4925 Robert J Mathews Pkwy., Suite 100
El Dorado Hills, CA 95762, USA

Contact:
Kimberley Gleeson
Regulatory Affairs Specialist
Phone: 1-916-404-8448
Fax: 1-916-357-7167
Email: kimberley.gleeson@haemonetics.com

Proposed Device Information:

Trade Name:	SafeTrace Tx 3.12.0 (Haemonetics Corporation)
Common Name:	Blood Establishment Computer Software (BECS)
Product Code:	MMH
Device:	Stand-alone Blood Bank Software
Review Panel:	Hematology
Device Class:	Unclassified

Predicate Device Information:

1.

Trade Name:	SafeTrace Tx 3.5.0
Common Name:	Blood Establishment Computer Software (BECS)
510(k) Number:	BK090026
Product Code:	MMH
Device:	Stand-alone Blood Bank Software
Review Panel:	Hematology
Device Class:	Unclassified

2.

Trade Name:	HCLL™ Transfusion, Version 2012
Common Name:	Software, Blood Bank, Stand Alone
510(k) Number:	BK120036
Product Code:	MMH
Device:	Stand-alone Blood Bank Software

Review Panel:	Hematology
Device Class:	Unclassified

Device Description

The proposed SafeTrace Tx 3.12.0 is an electronic information system intended to manage the transfusion process, including maintaining a complete test and transfusion history for a patient. The software application supports tracking of items needed to manage the transfusion process from receipt to final disposition.

Intended Use:

SafeTrace Tx is an electronic information system used by single-site, multi-site and centralized transfusion services to manage the blood transfusion process. It manages and tracks blood product information from receipt to final shipment and disposition.

Indications for Use:

SafeTrace Tx is an electronic information system that manages the blood transfusion process and assists in the determination of the suitability of released products. It manages and tracks blood product information relating to receipt, reservation, modification, testing (including reagent quality control), and final shipment and disposition. The application manages and provides a centralized view of patient, visit, and order information, including positive patient identification and patient, testing and transfusion history.

The system can perform electronic crossmatching and safety and compatibility checks between patient and product. Component attributes, such as human leukocyte antigen (HLA) attributes, can be entered into SafeTrace Tx. Users can search for components and subsequently reserve them for patients.

SafeTrace Tx can operate stand-alone or interface with:

- Labeling systems
- Test lab systems, analyzers, and equipment
- Irradiation devices
- Other Blood Establishment Computer Software (BECS) systems
- Hospital information systems
- Laboratory information systems
- Blood tracking and/or storage devices

Substantial Equivalence

The proposed software device, SafeTrace Tx 3.12.0, is substantially equivalent to the software devices Haemonetics SafeTrace Tx 3.5.0 (Predicate 1) and Mediware HCLL Transfusion, Version 2012 (Predicate 2).

The proposed SafeTrace Tx 3.12.0 uses similar technology as its predicate devices. While there are minor differences in technological characteristics and principles of operation between the proposed device and its predicate devices, none of these differences raise new types of safety or effectiveness questions. This demonstrates that the technology used in the proposed SafeTrace Tx 3.12.0 software device is substantially equivalent to the technology used in one or more of the predicate devices.

The proposed SafeTrace Tx 3.12.0 software device and its predicates are equivalent to or the same with respect to mapped intended use, functionality, performance, and technological characteristics, as well as safety and effectiveness.

Clinical Trials

Clinical performance testing is not applicable for SafeTrace Tx 3.12.0, as it is a software only product.

Conclusion

The proposed device, SafeTrace Tx 3.12.0, was developed in accordance with 820.30 Design Controls as well as the *"FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005)."* The software was thoroughly tested including verification, validation, and user acceptance (Beta) testing to ensure it is as safe, as effective, and performed as well as each predicate device`s functionality, when utilized within its intended use and in accordance with labeling, as demonstrated by the testing performed.

Based on the functionality and performance comparison, technological characteristics comparison and the intended use, the proposed SafeTrace Tx 3.12.0 device performs as intended in all aspects of the predicate devices' mapped functionality characteristics. The safety aspects of the proposed SafeTrace Tx 3.12.0 device have been thoroughly tested in accordance with validation practices as outlined in 820.30, Design Controls. The proposed SafeTrace Tx 3.12.0 software device is substantially equivalent to the predicate devices in terms of intended use, functionality, performance, technological characteristics as well as safety and effectiveness.